Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
USDA confirmed highly pathogenic Avian influenza in Massachusetts, Wyoming, North Carolina, Ohio and North Dakota
On Mar. 30, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed the…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
US Food and Drug Administration revised EUA for sotrovimab due to Omicron BA.2 subvariant
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration had amended…
USDA confirmed highly pathogenic Avian influenza in Minnesota
On Mar. 25, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
Pfizer supplied UNICEF 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-Income countries
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
Twist Bioscience launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in imagene’s stainless steel capsules
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
Researchers generated the first complete, gapless sequence of a human genome
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
The Priestley Medal was awarded to Peter B. Dervan
On Mar. 20, 2022, the American Chemical Society awarded The Priestley Medal to Peter B. Dervan “to recognize…
Johnson & Johnson announced acquisition of Tibotec-Virco NV for $320 million in cash and debt
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
Biotechnology | Infectious Disease | Polio | Vaccine | WHO
More than 80 million doses administered to southern African children targeted in mass polio vaccination drives
On Mar. 18, 2022, the World Health Organization (WHO) announced that Malawi had launched the first round of…
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
USDA confirmed highly pathogenic Avian influenza in non-commercial backyard flock (Non-Poultry) in New Hampshire
On Mar. 17, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed (APHIS)…
Moderna submited amendment to EUA for an additional booster dose of its COVID-19 vaccine in the U.S.
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
USDA confirmed highly pathogenic Avian influenza non-commercial backyard fock in Nebraska
On Mar. 16, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
USDA confirmed highly pathogenic Avian influenza in Wisconsin
On Mar. 14, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection (APHIS) Service confirmed…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
USDA confirmed highly pathogenic Avian influenza in Kansas and Illinois
On Mar. 10, 2022, the Illinois Department of Agriculture (IDOA), in conjunction with the Illinois Department of Natural…
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…